2 recruiting, 1 terminated, 1 unknown. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow epalrestat: new trials by email Literature Review of epalrestat trials Research Report on epalrestat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes Epalrestat, Donafenib + Tislelizumab, HAIC - HCC - Hepatocellular Carcinoma, Diabetes | Phase 2 | Recruiting | Haibo Shao | 32 | 2026-01-21 | 2026-11-10 |
| Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy. Nebivolol+ Standard care arm, Epalrestat + Alpha Lipoic Acid +Standard care, Standard care alone - Diabetic Neuropathy Peripheral | Phase 2 / Phase 3 | Recruiting | St. John's Research Institute | 120 | 2024-11-15 | 2025-02-04 |
| Research of SORD-CMT Natural History and Epalrestat Treatment Epalrestat - Charcot-Marie-Tooth Disease (CMT) | Phase 2 | Unknown | The Third Xiangya Hospital of Central South University | 30 | 2023-04-01 | 2023-04-18 |
| Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer Epalrestat - Triple Negative Breast Cancer | Phase 2 | Terminated | Sun Yat-sen University | 12 | 2017-03-01 | 2021-01-29 |
Carcinoma, Hepatocellular (1) · Charcot-Marie-Tooth Disease (1) · Diabetes Mellitus (1) · Triple Negative Breast Neoplasms (1)
Haibo Shao (1) · St. John's Research Institute (1) · Sun Yat-sen University (1) · The Third Xiangya Hospital of Central South University (1)
China (2) · India (1)
Haibo Shao (1) · Tao Han (1)